Frankfurt
08.10.25 | 08:08
5,550 Euro
0,00 % 0,000
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 30.09. | Nxera Pharma Announces Second Milestone In AbbVie Neurology Collaboration, Secures $10 Mln Payment | 354 | AFX News | TOKYO (dpa-AFX) - Nxera Pharma Co., Ltd. (SOLTF, 4565.T) announced it has reached a second milestone in its multi-target discovery collaboration with AbbVie focused on neurological diseases.... ► Artikel lesen | |
| NXERA PHARMA Aktie jetzt für 0€ handeln | |||||
| 30.09. | Nxera Pharma to Receive US$10 Million Milestone Payment from AbbVie under Collaboration Targeting Neurological Diseases | 111 | GlobeNewswire (Europe) | Tokyo, Japan and Cambridge and London, UK, 30 September 2025 - Nxera Pharma Co., Ltd. ("Nxera" or "the Company"; TSE 4565) announces that it has reached a second important R&D milestone under its... ► Artikel lesen | |
| 18.09. | Singtel's Nxera secures $643m green loan for DC Tuas data centre | 6 | Singapore Business Review | ||
| 17.09. | Nxera Pharma and Cancer Research UK Announce First Patient Dosed in Phase 2a Trial of Investigational Cancer Immunotherapy HTL0039732 | 141 | GlobeNewswire (Europe) | HTL0039732 (also known as NXE0039732) is Nxera's novel oral EP4 antagonist being investigated to treat a wide range of solid cancers in combination with other immunotherapiesCancer Research UK's Centre... ► Artikel lesen | |
| 08.08. | Nxera Pharma reports Q2 results | 1 | Seeking Alpha | ||
| 08.08. | Nxera Pharma Operational Highlights and Consolidated Results for the Second Quarter and First Half 2025 | 156 | GlobeNewswire (Europe) | Tokyo, Japan and Cambridge, UK, 8 August 2025 - Nxera Pharma ("the Company" or "Nxera"; TSE: 4565) provides an update on operational activities and reports its consolidated results for the second... ► Artikel lesen | |
| 06.08. | Nxera debuts an obesity pipeline; BridgeBio battles Alynam for market share | 18 | BioPharma Dive | ||
| 06.08. | Nxera Pharma: Nxera Launches Broad Proprietary Pipeline Targeting Obesity and Chronic Weight Management | 174 | GlobeNewswire (Europe) | Pipeline led by a new proprietary oral small molecule GLP-1 agonist and six additional innovative programs targeting the GIP, Amylin and Apelin receptors, aiming to transform treatment landscapeDesigned... ► Artikel lesen | |
| 29.07. | Singtel's Data Centre Arm Nxera Embarks on Ambitious Hiring Plan for AI Skills | 1 | The Fast Mode | ||
| 04.07. | Nxera Pharma To Receive $4.8 Mln Milestone As Centessa Advances ORX142 To Phase 1 Study | 2 | RTTNews | ||
| 04.07. | Nxera Pharma to Receive US$4.8 Million in Milestone Payments Following Centessa's Initiation of Clinical Development of ORX142, a Novel Orexin Receptor 2 (OX2R) Agonist | 240 | GlobeNewswire (Europe) | Tokyo, Japan and Cambridge, UK, 4 July 2025 - Nxera Pharma Co., Ltd. ("Nxera" or "the Company"; TSE 4565) today announces that it will receive US$4.8 million in milestone payments from Centessa Pharmaceuticals... ► Artikel lesen | |
| 03.06. | Nxera Hits Important Milestone in Diabetes Drug Partnership with Eli Lilly | 9 | Insider Monkey | ||
| 03.06. | Nxera Pharma to Receive US$15 Million from Neurocrine Biosciences Following Dosing of First Patient in Phase 3 Trial of NBI-1117568 | 198 | GlobeNewswire (Europe) | Tokyo, Japan and Cambridge, UK, 3 June 2025 - Nxera Pharma Co., Ltd. ("Nxera" or "the Company"; TSE 4565) today announces that its partner, Neurocrine Biosciences ("Neurocrine") has dosed the first... ► Artikel lesen | |
| 02.06. | Nxera Pharma Reaches Key Milestone In Lilly Partnership For Diabetes & Metabolic Disease Research | 581 | AFX News | INDIANAPOLIS (dpa-AFX) - Nxera Pharma Co., Ltd. announced that it has achieved a development milestone under its multi-target collaboration and license agreement with Eli Lilly and Co. (LLY)... ► Artikel lesen | |
| 02.06. | Nxera Pharma Achieves Development Milestone in Collaboration with Eli Lilly Targeting Metabolic Diseases | 263 | GlobeNewswire (Europe) | Tokyo, Japan and Cambridge, UK, 2 June 2025 - Nxera Pharma Co., Ltd. ("Nxera" or "the Company"; TSE 4565) today announces that it has achieved a development milestone under its multi-target collaboration... ► Artikel lesen | |
| 02.05. | Nxera Pharma Operational Highlights and Consolidated Results for the First Quarter 2025 | 221 | GlobeNewswire (Europe) | Tokyo, Japan and Cambridge, UK, 2 May 2025 - Nxera Pharma ("the Company" or "Nxera"; TSE: 4565) provides an update on operational activities and reports its consolidated results for the first quarter... ► Artikel lesen | |
| 01.05. | Nxera Pharma's Partner Neurocrine Biosciences Initiates Phase 3 Registrational Program of NBI-1117568 as a Potential Treatment for Adults with Schizophrenia | 259 | GlobeNewswire (Europe) | NBI-1117568 is an oral, muscarinic M4 selective receptor agonist discovered by Nxera advancing through clinical development under a multi-program collaboration with NeurocrineFor more information... ► Artikel lesen | |
| 01.05. | Nxera Pharma Appoints Top-Ranked Biopharma Investment Analyst Shinya Tsuzuki as Head of Investor Relations | 1 | GlobeNewswire (USA) | ||
| 25.03. | Nxera Pharma's Partner Tempero Bio Initiates Phase 2 Trial with TMP-301 for Alcohol Use Disorder | 332 | GlobeNewswire (Europe) | Tokyo, Japan and Cambridge, UK, 25 March 2025 - Nxera Pharma Co., Ltd. ("Nxera" or "the Company"; TSE 4565) announces that its partner Tempero Bio, Inc. has initiated a Phase 2 trial of TMP-301, a... ► Artikel lesen | |
| 14.02. | Nxera Pharma Operational Highlights and Consolidated Results for the Fourth Quarter and Full Year 2024 | 451 | GlobeNewswire (Europe) | Tokyo, Japan and Cambridge, UK, 14 February 2025 - Nxera Pharma Co., Ltd. ("Nxera" or "the Company"; TSE 4565) provides an update on operational activities and reports its consolidated results for... ► Artikel lesen |
1 2 Weiter >>
23 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| PFIZER | 22,345 | -0,89 % | Pfizer: Deal mit Trump - Aktie mit Kurssprung | Die US-Regierung hat am Dienstag eine Vereinbarung mit dem Pharmakonzern Pfizer über günstigere Arzneimittel bekanntgegeben. Laut Trump werden Medikamente von Pfizer künftig zu reduzierten Preisen im... ► Artikel lesen | |
| NOVARTIS | 114,46 | +1,24 % | AKTIEN IM FOKUS: Pharmawerte proftieren von US-Deal mit Pfizer | FRANKFURT/ZÜRICH (dpa-AFX) - Europas Pharmawerte haben am Mittwoch stark von einem Deal zwischen der US-Regierung und Pfizer profitiert. Der Branchenindex Stoxx Europe 600 Health Care holte fast seine... ► Artikel lesen | |
| GILEAD SCIENCES | 101,00 | +0,74 % | RBC Capital raises Gilead Sciences stock price target to $100 on Yeztugo launch | ||
| SANOFI | 84,35 | -0,06 % | Aktienmarkt: Starke Nachfrage treibt Kurs der Sanofi SA-Aktie (81,98 €) | Grund zur Freude haben Inhaber dem Anteilsschein von Sanofi SA : Der Titel steigt deutlich. Zu den Performancebesten am Aktienmarkt zählt gegenwärtig das Wertpapier von Sanofi SA. Im Vergleich zum letzten... ► Artikel lesen | |
| ABBVIE | 199,20 | -0,40 % | AbbVie Says Phase 2 ELATE Trial Met Primary Endpoint For BOTOX To Treat Upper Limb Essential Tremor | WASHINGTON (dpa-AFX) - AbbVie, Inc. (ABBV) announced Monday positive topline results from the Phase 2 ELATE trial evaluating the safety and efficacy of onabotulinumtoxinA (BOTOX) compared to... ► Artikel lesen | |
| ROCHE | 313,10 | +1,16 % | JPMORGAN stuft ROCHE HOLDINGS AG auf 'Underweight' | NEW YORK (dpa-AFX Analyser) - Die US-Bank JPMorgan hat die Einstufung für Roche nach einem Gespräch mit dem Vorstandsvorsitzenden des Pharmakonzerns auf "Underweight" mit einem Kursziel von 230 Franken... ► Artikel lesen | |
| ABBOTT LABORATORIES | 114,84 | +0,58 % | UBS reiterates Buy rating on Abbott Labs stock, citing undervalued growth | ||
| INCYTE | 73,76 | -1,44 % | Oppenheimer stuft Incyte-Aktie auf 'Perform' herab | ||
| EDWARDS LIFESCIENCES | 64,99 | -1,31 % | Edwards Lifesciences slips as Oppenheimer downgrades on upcoming data | ||
| WPD PHARMACEUTICALS | 0,002 | 0,00 % | WPD Pharmaceuticals Inc (2): WPD Pharmaceuticals suspended by CSE | ||
| HALEON | 3,900 | +2,85 % | Haleon plc and Salesforce: Haleon Selects Salesforce Agentforce Life Sciences Cloud for Customer Engagement to Improve Engagement with Pharmacies and Healthcare Professionals with AI | Haleon plc (LSE/NYSE:HLN), a leading global consumer company that specialises in everyday health and Salesforce (NYSE:CRM), the world's #1 AI CRM, today announced that Haleon will leverage Salesforce... ► Artikel lesen | |
| BIONANO GENOMICS | 2,020 | +0,50 % | Bionano Genomics: Bionano to Participate in the H.C. Wainwright @ Home Event | ||
| TONIX PHARMACEUTICALS | 19,800 | 0,00 % | Tonix to advance cyclobenzaprine into phase 2 for depression | ||
| GRIFOLS | 12,330 | +0,82 % | EQS-News: Biotest AG: Einberufung einer außerordentlichen Hauptversammlung auf Verlangen der Grifols S.A. | EQS-News: Biotest AG
/ Schlagwort(e): Hauptversammlung
Biotest AG: Einberufung einer außerordentlichen Hauptversammlung auf Verlangen der Grifols S.A.
19.09.2025... ► Artikel lesen | |
| ALNYLAM PHARMACEUTICALS | 390,40 | -1,04 % | 27 Analysts Assess Alnylam Pharmaceuticals: What You Need To Know |
Das Unternehmen NXERA PHARMA CO LTD kann der Branche Pharma zugeordnet werden. Die relative Kursveränderung beträgt aktuell 0,00 % bei einem Aktienkurs von 5,550 Euro. Beim derzeitigen Kurs ergibt sich, basierend auf einer gesamten Ausschüttung von 0,00 Euro in den vergangenen 12 Monaten, eine Dividendendrendite von 0,00 %.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu NXERA PHARMA CO LTD finden Sie auf Wallstreet Online.